These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38877367)
1. Impaired angiotensin II signaling in septic shock. Picod A; Garcia B; Van Lier D; Pickkers P; Herpain A; Mebazaa A; Azibani F Ann Intensive Care; 2024 Jun; 14(1):89. PubMed ID: 38877367 [TBL] [Abstract][Full Text] [Related]
2. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock. Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822 [TBL] [Abstract][Full Text] [Related]
3. The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications. Garcia B; Zarbock A; Bellomo R; Legrand M Crit Care; 2023 Nov; 27(1):453. PubMed ID: 37986086 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock. Chow JH; Wallis M; Lankford AS; Chancer Z; Barth RN; Scalea JR; LaMattina JC; Mazzeffi MA; McCurdy MT Semin Cardiothorac Vasc Anesth; 2021 Mar; 25(1):67-73. PubMed ID: 32787515 [TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial. Coulson TG; Miles LF; Zarbock A; Burrell LM; Patel SK; von Groote T; Pilcher D; Weinberg L; Landoni G; Bellomo R Br J Anaesth; 2023 Oct; 131(4):664-672. PubMed ID: 37481435 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors. Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825 [TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. Boorsma EM; Ter Maaten JM; Damman K; van Veldhuisen DJ; Dickstein K; Anker SD; Filippatos G; Lang CC; Metra M; Santos K; Voors AA Eur J Heart Fail; 2021 Jun; 23(6):947-953. PubMed ID: 33742751 [TBL] [Abstract][Full Text] [Related]
8. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Ferrario CM; Mullick AE Pharmacol Res; 2017 Nov; 125(Pt A):57-71. PubMed ID: 28571891 [TBL] [Abstract][Full Text] [Related]
9. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management. Senatore F; Balakumar P; Jagadeesh G Pharmacol Res; 2021 Dec; 174():105916. PubMed ID: 34597810 [TBL] [Abstract][Full Text] [Related]
10. Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock. Pode-Shakked N; Ceschia G; Rose JE; Goldstein SL; Stanski NL; Crit Care; 2023 Jun; 27(1):230. PubMed ID: 37308975 [TBL] [Abstract][Full Text] [Related]
11. Dysfunction of the renin-angiotensin-aldosterone system in human septic shock. Schaich CL; Leisman DE; Goldberg MB; Filbin MR; Khanna AK; Chappell MC Peptides; 2024 Jun; 176():171201. PubMed ID: 38555976 [TBL] [Abstract][Full Text] [Related]
12. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033 [TBL] [Abstract][Full Text] [Related]
13. Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Salgado DR; Rocco JR; Silva E; Vincent JL Expert Opin Ther Targets; 2010 Jan; 14(1):11-20. PubMed ID: 20001206 [TBL] [Abstract][Full Text] [Related]
14. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Lee AF; MacFadyen RJ; Struthers AD Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503 [TBL] [Abstract][Full Text] [Related]
16. The role of renin-angiotensin system in sepsis-associated acute kidney injury: mechanisms and therapeutic implications. Garcia B; Zarbock A; Bellomo R; Legrand M Curr Opin Crit Care; 2023 Dec; 29(6):607-613. PubMed ID: 37861190 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of angiotensin II type 1 receptors during sepsis. Bucher M; Ittner KP; Hobbhahn J; Taeger K; Kurtz A Hypertension; 2001 Aug; 38(2):177-82. PubMed ID: 11509472 [TBL] [Abstract][Full Text] [Related]
18. Hypertension: renin-angiotensin-aldosterone system alterations. Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283 [TBL] [Abstract][Full Text] [Related]